logo
Piedmont Columbus Regional Midtown project reaches half-way point with 23 new ICU beds

Piedmont Columbus Regional Midtown project reaches half-way point with 23 new ICU beds

Yahoo06-02-2025
COLUMBUS, Ga. () — If you have been to the Piedmont Columbus Regional Midtown campus, you have undoubtedly noticed the crane and the construction. WRBL had an exclusive look at the progress on Wednesday.
This is a $58 million project that started a year ago. Brasfield & Gorie is renovating or constructing 99,038 square feet of hospital space. It's expected to bring 43 new ICU beds and a renovated 15-bed unit for oncology patients.
That is to say — if this was a football game, it's now halftime.
WRBL caught up with a man born at The Medical Center. He now plays an integral role in the renovation of the hospital.
'And it's kind of strange to be 42 years later, the place I was born,' said Brandon Boswell, a Brasfield & Gorie Superintendent. 'Building a new ICU expansion for the place I was born and the place that I'll be if anything happens to me. And I need health care. This is where I will be.'
That is one of the significant pieces of this hospital construction project for many of the Brasfield & Gorrie employees and subcontractors.
'There's a lot of local subcontractors that are participating in this project. Our whole team from management staff live in Columbus, either born in Columbus or currently live in Columbus,' said Boswell. 'This is the hospital that our families come to. You know, my grandma could be, you know, up in one of these ICU beds, one of these days. My kids have frequently visited this E.R. over the past few years.'
Boswell told us it added more of a personal aspect to the decision-making involved in working with the hospital, saying 'at the end of the day, when we're done, we could be in this hospital.'
When you go on a construction site, you don't normally think about community. But – as you heard – you do on this one.
Another unusual aspect of this construction site is that a lot of the work is being done while the hospital continues its operations.
To Brasfield & Gorrie Project Manager Chris Strong, hospital projects in general are special.
'The first thing you have to do for front and center every day is the patient experience, patient care. And you just have to plan around that,' said Strong. 'I mean, we've taken over an entire floor of an active hospital in the middle of flu season right now. So as you can imagine, the bed crunch is is pretty pretty tight for them right now.'
Strong says the tower was not originally planned to go vertical when it was constructed, so a lot of the front-end work went into the design.
'…as far as how much weight we could add to the building,' Strong told WRBL. 'How much, you know, what all would we have to do inside the hospital to fit the structure to allow for the vertical expansion.'
The first large piece of the project is almost complete. Twenty-three ICU beds, as well as a renovated floor, will all be ready next month.
For construction workers this is a difficult, yet rewarding project.
'Health care construction is more about communications than other types of construction, in my opinion,' said Strong. 'Just because there are so many different elements and so many different people, you're affecting, you know, advertently, inadvertently, when you're when you're building the project.'
One particularly impressive components of this construction is the addition of a seventh floor to the east side. Because this building was built in the mid-1970s, they are essentially building a new foundation six floors up.
All in all, the massive project is a classic example of short-term pain for long-term gain.
'Construction is difficult at best to try to dovetail it in with our normal activities. But to date, we've been very successful,' said Piedmont Columbus Regional Chief Nursing Officer Cary Burcham. 'We've done multiple construction projects on this campus in the last year and a half. And so disruptions are becoming sort of the new normal.'
Burcham says they've tried to create an environment that helps eases the fear of being in a hospital.
'Whenever you have a loved one in the ICU, it's scary, it's terribly scary. And when you walk in into an environment like this, what we've tried to create is an environment that is high tech, yet very comforting and instills confidence,' said Burcham. 'They have the space to do what they need to do. They have the equipment to do what they need to do. It looks functional, and I know that my loved one is receiving the best care that they can receive.'
And that attention to detail can be seen by new patient lifts that will offer caregivers a better way to treat those in the ICU.
'What we do right now to lift patients is very manual and we wanted to have automated equipment that would allow us to begin to normalize patients as they get well,' said Burcham. 'This lift equipment will move not only left to right, but front to back so that we can move patients to a bedside chair. We can take them to the bathroom, we can prepare them for early ambulation out in the hallway. So these are devices that we do not have currently today.'
The reward? The hospital and its staff knowing when this is done, it will create better care for patients.
Once again, it comes back to community.
'…there's an incredible sense of pride that we have as a trauma center and as a safety net hospital to meet the needs of our community,' said Burcham. 'And we take it very seriously. And I think the project that we've designed here is a huge step in that direction.'
This is a 24-month project that came on the heels of an 18-month project to open the Bill and Olivia Amos Children's Hospital in the old Doctors Hospital space. It's scheduled to be completed next spring.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Aflac Incorporated Announces Increase in Shares Authorized for Repurchase
Aflac Incorporated Announces Increase in Shares Authorized for Repurchase

Yahoo

timea day ago

  • Yahoo

Aflac Incorporated Announces Increase in Shares Authorized for Repurchase

COLUMBUS, Ga., Aug. 12, 2025 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) today announced that its Board of Directors has authorized the purchase of up to 100 million shares of its common stock. This authorization is in addition to the 30.9 million shares as of June 30, 2025, that remained under the November 8, 2022 authorization, bringing the total number of shares available for purchase to approximately 130.9 million. The company anticipates that the repurchase of shares will be conducted from time to time in open market or negotiated transactions, depending on market conditions. ABOUT AFLAC INCORPORATED Aflac Incorporated (NYSE: AFL), a Fortune 500 company, has helped provide financial protection and peace of mind for nearly seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan. In the U.S., Aflac is the No. 1 provider of supplemental health insurance products.1 In Japan, Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force. The company takes pride in being there for its policyholders when they need us most, as well as being included in the World's Most Ethical Companies by Ethisphere for 19 consecutive years (2025) and Fortune's World's Most Admired Companies for 24 years (2025). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been included in the Dow Jones Sustainability North America Index (2024) for 11 years. To find out how to get help with expenses health insurance doesn't cover, get to know us at or Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at under "Sustainability." 1 LIMRA 2024 U.S. Supplemental Health Insurance Total Market Report FORWARD-LOOKING INFORMATION The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. Aflac Incorporated (the Parent Company) and its subsidiaries (collectively with the Parent Company, the Company) desire to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by Company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as "expect," "anticipate," "believe," "goal," "objective," "may," "should," "estimate," "intends," "projects," "will," "assumes," "potential," "target," "outlook" or similar words as well as specific projections of future results, generally qualify as forward-looking. The Company undertakes no obligation to update such forward-looking statements. The Company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements: difficult conditions in global capital markets and the economy, including inflation defaults and credit downgrades of investments global fluctuations in interest rates and exposure to significant interest rate risk concentration of business in Japan limited availability of acceptable yen-denominated investments foreign currency fluctuations in the yen/dollar exchange rate differing interpretations applied to investment valuations significant valuation judgments in determination of expected credit losses recorded on the Company's investments decreases in the Company's financial strength or debt ratings decline in creditworthiness of other financial institutions the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners deviations in actual experience from pricing and reserving assumptions ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality, integrity or privacy of sensitive data residing on such systems, and uncertainty regarding the impact of the incident involving unauthorized access to the Company's network in June 2025 subsidiaries' ability to pay dividends to the Parent Company inherent limitations to risk management policies and procedures operational risks of third-party vendors tax rates applicable to the Company may change failure to comply with restrictions on policyholder privacy and information security extensive regulation and changes in law or regulation by governmental authorities competitive environment and ability to anticipate and respond to market trends catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events ability to protect the Aflac brand and the Company's reputation ability to effectively manage key executive succession changes in accounting standards level and outcome of litigation or regulatory inquiries allegations or determinations of worker misclassification in the United States Analyst and investor contact - David A. Young, 706.596.3264 or 800.235.2667 or dyoung@ Media contact – Ines Gutzmer, 762.207.7601 or igutzmer@ View original content to download multimedia: SOURCE Aflac Incorporated

BD commits $35M to expand US syringe production plant
BD commits $35M to expand US syringe production plant

Yahoo

time6 days ago

  • Yahoo

BD commits $35M to expand US syringe production plant

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: BD is investing more than $35 million to expand production of prefilled flush syringes at a facility in Columbus, Nebraska, the company said Monday. The investment will add around 50 jobs at the site and equip BD to make hundreds of millions of additional units a year to meet growing demand from U.S. hospitals and health systems. BD framed the spending as part of an ongoing commitment to its Posiflush line, which has seen it invest more than $80 million to expand production of the syringes over the past three years. Dive Insight: Healthcare professionals use flush syringes to stop vascular access systems from becoming blocked and to help remove medication that is left at the catheter site. The resilience of the industry's supply chain came under scrutiny when Cardinal Health's 2021 recall of Monoject devices led to a shortage that persisted in 2023 and drove the FDA to share strategies for conserving the devices. Against that backdrop, BD has increased its U.S. Posiflush production capacity. The company said it has grown capacity by 10% this year, bringing its total U.S. output of the prefilled flush syringes to above 750 million units. Last year, BD added new needle and syringe production lines at plants in Connecticut and Nebraska as part of a more than $10 million investment. The latest investment comes three months after BD said it would invest $2.5 billion in U.S. manufacturing over the next five years. This week's $35 million commitment is part of a series of vows by companies to invest in manufacturing in the U.S. amid the threat and imposition of tariffs. Yet BD has warned that tariffs are actually causing it to relocate some production from the Nebraska plant to overseas facilities. BD CEO Tom Polen explained how tariffs are moving some production out of the U.S. at an event hosted by Goldman Sachs in June. 'Historically our flush syringes always came out of Columbus, Nebraska, and we would ship those to China. We have a facility now in China that's going to source just for China for that,' Polen said. 'I think there's more downside to tariff impacts from a U.S. manufacturing perspective in the medtech industry than there are in many others.' Recommended Reading Waters, BD biosciences unit agree to $17.5B merger

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store